Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milnacipran (Xianweining) for major depressive disorder
ChiCTR2600121247Phase 4Completed
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of milnacipran in major depressive disorder (MDD), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Change in Hamilton Depression Rating Scale-17 (HAMD-17) score at week 6. Started Mar 2026; status: completed.
02
Drugs
milnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600121247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121247.